Table 2.
Clinical characteristics of the two study participants who tested negative for autoantibodies (GADA, IA-2A, and ICA) at 1 month and who converted to positivity for GADA (patient 2) at 12 months or IA-2A (patient 24 (carrier of the Arg1530Cys mutation of the ABCC8)) at 6 and 12 months after the diagnosis of type 1 diabetes
| Patient | Age (years) |
Sex | BMI (kg/m2) |
HbA1C0 (%) |
IDAA1C 1 | IDAA1C 6 | IDAA1C 12 | Ins dose1 (U/kg/day) |
ins dose6 (U/kg/day) |
Ins dose12 (U/kg/day) |
Cpep1 (pmol/L) |
Cpep6 (pmol/L) |
Cpep12 (pmol/L) |
BGstim1 (mmol/L) |
BGstim6 (mmol/L) |
BGstim12 (mmol/L) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2 | 16.3 | female | 17 | 10.9 | Na | 11.1 | 11.7 | 0.54 | 0.73 | 0.59 | 120 | 10 | 10 | 14.2 | 20.7 | 13.2 |
| 24 | 14 | male | 16.4 | 12.4 | 11.3 | 10.6 | 12.8 | 0.63 | 0.73 | 0.98 | 356 | 308 | 218 | 13.9 | 21 | 20.6 |
Abbreviations: Na, not available; BMI, body mass index; HBA1C0; HBA1C at diagnosis; IDAA1C 1, Insulin Dose Adjusted HbA1c (IDAA1C) at 1 month; IDAA1C 6, IDAA1C at 6 months; IDAA1C 12, IDAA1C at 12 months;; Ins dose1, insulin dose at 1 month; Ins dose6, insulin dose at 6 months; Ins dose12, insulin dose at 12 months; Cpep1, stimulated C-peptide at 1 month, Cpep6, stimulated C-peptide at 6 months; Cpep12, stimulated C-peptide at 12 months; BGstim1, 90 min glucose at 1 month; BGstim6, 90 min glucose at 6 months; BGstim12, 90 min glucose at 12 months;